Novartis Pharma AG 13D and 13G filings for CELLULAR BIOMEDICINE GROUP, IN:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2021-02-23 7:57 pm Sale | 2021-02-19 | 13D | CELLULAR BIOMEDICINE GROUP, IN CBMG | Novartis Pharma AG | 0 0.000% | -1,458,257 (Position Closed) | Filing |
| 2020-08-14 4:32 pm Unchanged | 2020-08-11 | 13D | CELLULAR BIOMEDICINE GROUP, IN CBMG | Novartis Pharma AG | 1,458,257 7.500% | 0 (Unchanged) | Filing |